Corbus Pharmaceuticals I... (CRBP)
NASDAQ: CRBP
· Real-Time Price · USD
9.25
-0.38 (-3.95%)
At close: Aug 15, 2025, 3:59 PM
9.43
1.95%
After-hours: Aug 15, 2025, 04:56 PM EDT
-3.95% (1D)
| Bid | 8.91 |
| Market Cap | 113.36M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -57.95M |
| EPS (ttm) | -4.76 |
| PE Ratio (ttm) | -1.94 |
| Forward PE | -1.69 |
| Analyst | Buy |
| Ask | 9.99 |
| Volume | 116,247 |
| Avg. Volume (20D) | 152,132 |
| Open | 9.66 |
| Previous Close | 9.63 |
| Day's Range | 9.10 - 9.80 |
| 52-Week Range | 4.64 - 61.89 |
| Beta | 3.21 |
About CRBP
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol CRBP
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for CRBP stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 months ago
-15.77%
Corbus Pharmaceuticals Holdings shares are trading...
Unlock content with
Pro Subscription
11 months ago
-62.26%
Corbus Pharmaceuticals Holdings shares are trading lower amid sympathy with Novo Nordisk after the company reported results from its Phase2a trial of Monlunabant in obesity. Also, Wedbush maintained an Outperform rating on the stock but lowered its price target from $85 to $51.
1 week ago · fool.com
Corbus (CRBP) Q2 Loss Beats EstimatesCorbus (CRBP) Q2 Loss Beats Estimates
2 months ago · seekingalpha.com
Corbus Pharmaceuticals: Is Its Pipeline Really Worthless After Novo's Negative Data?CRBP's pipeline shows promise, especially CRB-701 with early signals of benefit and tolerability, but all programs remain in early clinical stages. The company's financial position is stable for now, ...
